Integrated Biopharma Financial Results
Integrated BioPharma reported a 22% revenue decline to $9.9 million for the quarter ended September 30, 2026, resulting in a net loss of $0.7 million. The company noted significant customer concentration, with its two largest contract manufacturing clients accounting for 88% of total revenue.
- Term
- Q1 2027
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”
Riva Sheppard and Christina Kay, Co-Chief Executive Officers